EMA Authorised: Mirapexin (pramipexole dihydrochloride monohydrate) — Boehringer Ingelheim International GmbH

View source ↗

Summary

The European Medicines Agency authorized Mirapexin (pramipexole dihydrochloride monohydrate) for restless legs syndrome and Parkinson's disease, with Boehringer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Restless Legs Syndrome

Drugs mentioned

• Mirapexin (pramipexole dihydrochloride monohydrate)

Snippet

Status: Authorised. Therapeutic area: Restless Legs Syndrome;Parkinson Disease. MAH: Boehringer Ingelheim International GmbH. Decision date: 14/03/2024